EXHIBIT 10.9
*CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS
Memorandum of Understanding
Supply and Services Agreement for ****1073
Summary
-------
**** will provide API development and manufacturing functions for
****1073 API to Corcept. This will include Non-GMP, as well as CGMP
products for pre-clinical, clinical and commercial requirements.
****1073 will be studied by Corcept for treating patients with
psychiatric and cognitive disorders only. In addition, **** is willing
to act as a consultant to introduce Corcept to reputable dosage form
manufacturers in **** for formulation development and manufacturing.
Project Plan
------------
1. **** and Corcept will jointly invest in the acquisition of starting
materials, equipment and manpower to complete the technology transfer,
process development and scale-up studies. The target date to deliver
total of **** Non-GMP materials for the planned toxicology study will
be August/September, 2000, with smaller quantities (****) possibly
available in July/August.
2. Produce **** of CGMP material by year-end of 2000 for clinical studies.
3. Prepare and submit DMF including all processing and analytical
information for product registration.
4. Introduce Corcept CMC representative(s) to **** dosage form
manufacturers and assist in selecting and establishing a direct working
relationship between Corcept and the selected manufacturer.
Development Out of Pocket Cost
------------------------------
Starting material/reagents etc. ****
Equipment & other supplies ****
**** Manpower **** ****
---------------------------------------------------------
Total **** (1)
(1) At **** shared costs, Corcept will pay $150,000
Product Costs
-------------
Non-GMP Materials ****
GMP Materials ****
**** Reduction to be negotiated.
Quantities
----------
1. Corcept will guarantee minimum purchase of 1 million dollars per year
following product launch.
2. **** 1073 volume purchase in calendar year 2001 could be in the range
of ****
3. **** 1073 purchase forecast, commencing calendar year 2003, will be
between **** annual requirements.
****, Ltd. Corcept Inc.
By /s/ **** By Xxxxxx Xxxxxxxx
Title President Title CEO
Date June 1, 2000 Date June 8, 2000
****
By /s/ ****
Title President
Date June 12, 2000
2
